Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics logo
$17.63 +1.66 (+10.39%)
Closing price 04:00 PM Eastern
Extended Trading
$17.50 -0.13 (-0.74%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viridian Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
1
Buy
12

Based on 14 Wall Street analysts who have issued ratings for Viridian Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a sell rating, 1 has given a hold rating, and 12 have given a buy rating for VRDN.

Consensus Price Target

$36.14
105.01% Upside
According to the 14 analysts' twelve-month price targets for Viridian Therapeutics, the average price target is $36.14. The highest price target for VRDN is $61.00, while the lowest price target for VRDN is $20.00. The average price target represents a forecasted upside of 105.01% from the current price of $17.63.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for VRDN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Viridian Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRDN Analyst Ratings Over Time

TypeCurrent Forecast
5/20/25 to 5/20/26
1 Month Ago
4/20/25 to 4/20/26
3 Months Ago
2/19/25 to 2/19/26
1 Year Ago
5/20/24 to 5/20/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
13 Buy rating(s)
13 Buy rating(s)
10 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$36.14$37.57$42.64$36.70
Forecasted Upside105.01% Upside155.94% Upside51.75% Upside165.56% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

VRDN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VRDN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Viridian Therapeutics Stock vs. The Competition

TypeViridian TherapeuticsMedical CompaniesBroader Market
Consensus Rating Score
2.79
2.29
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside126.32% Upside1,742.64% Upside17.79% Upside
News Sentiment Rating
Neutral News

See Recent VRDN News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
5/15/2026
Evercore Inc logo
Evercore
4 of 5 stars
 Set Target$26.00+53.87%
5/13/2026
Stifel Nicolaus logo
Stifel Nicolaus
4 of 5 stars
 Set Target$39.00+129.63%
5/6/2026
Lisa Walter
Lisa Walter
Not Rated
Boost TargetOutperform$30.00 ➝ $34.00+81.12%
5/5/2026Reiterated RatingBuy$32.00+70.47%
4/21/2026Lower TargetBuy$36.00 ➝ $33.00+124.80%
4/20/2026 Reiterated RatingSell (D-)
4/8/2026Lower TargetOutperform$37.00 ➝ $31.00+122.06%
4/7/2026Lower TargetBuy$36.00 ➝ $31.00+120.48%
3/31/2026Lower TargetEqual Weight$29.00 ➝ $20.00+6.29%
3/31/2026Lower TargetBuy$34.00 ➝ $22.00+18.73%
Why Elon just bought a power plant (Ticker inside) (Ad)

Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer without equipment that typically has a 2-year lead time — so he shipped an entire industrial power plant across the Atlantic Ocean. One small company holds a $1.5 billion backlog for the exact hardware Musk's 'Colossus' site needs to scale. Wall Street still prices it like a sleepy industrial stock, but a June IPO could change that fast.tc pixel

See the ticker tied to Musk's power crisis before June arrives
1/7/2026Initiated CoverageBuy$50.00+61.06%
12/3/2025Initiated CoverageOutperform
11/4/2025Reiterated RatingBuy$61.00+163.50%
10/21/2025Boost TargetOutperform$32.00 ➝ $36.00+46.54%
8/25/2025 Initiated CoverageBuy$44.00+127.39%
5/7/2025Lower TargetMarket Outperform$42.00 ➝ $38.00+209.32%
11/25/2024Initiated CoverageBuy
6/11/2024 Initiated CoverageOutperform$29.00+137.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:27 PM ET.


VRDN Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Viridian Therapeutics is $36.14, with a high forecast of $61.00 and a low forecast of $20.00.

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last twelve months. There is currently 1 sell rating, 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VRDN shares.

According to analysts, Viridian Therapeutics's stock has a predicted upside of 105.01% based on their 12-month stock forecasts.

Viridian Therapeutics has been rated by research analysts at Evercore, HC Wainwright, Needham & Company LLC, Royal Bank Of Canada, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Viridian Therapeutics more than other "medical" companies. The consensus rating for Viridian Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how VRDN compares to other companies.


This page (NASDAQ:VRDN) was last updated on 5/20/2026 by MarketBeat.com Staff.
From Our Partners